Albemarle (ALB) – Research Analysts’ Recent Ratings Updates

Albemarle (NYSE: ALB) has recently received a number of price target changes and ratings updates:

• 2/12/2025 – Albemarle had its price target lowered by analysts at Royal Bank of Canada from $133.00 to $114.00. They now have an “overweight” rating on the stock.
• 2/12/2025 – Albemarle had its price target lowered by analysts at Robert W. Baird from $103.00 to $92.00. They now have a “neutral” rating on the stock.
• 2/12/2025 – Albemarle had its price target lowered by analysts at Citigroup Inc. from $115.00 to $85.00. They now have a “neutral” rating on the stock.
• 2/12/2025 – Albemarle had its price target lowered by analysts at BMO Capital Markets from $150.00 to $140.00.
• 2/12/2025 – Albemarle had its price target lowered by analysts at Deutsche Bank Aktiengesellschaft from $109.00 to $105.00.
• 2/5/2025 – Albemarle was downgraded by analysts at Evercore ISI from an “outperform” rating to an “inline” rating.
• 1/28/2025 – Albemarle is now covered by analysts at Truist Financial Co.. They set a “hold” rating and a $96.00 price target on the stock.
• 1/14/2025 – Albemarle is now covered by analysts at Clarkson Capital. They set a “buy” rating and a $112.00 price target on the stock.
• 1/7/2025 – Albemarle had its price target lowered by analysts at Mizuho from $110.00 to $105.00. They now have a “neutral” rating on the stock.
• 12/18/2024 – Albemarle had its price target raised by analysts at Robert W. Baird from $79.00 to $103.00. They now have a “neutral” rating on the stock.

Albemarle Trading Up 1.1 %

NYSE ALB opened at $76.57 on Thursday. Albemarle Co. has a one year low of $71.97 and a one year high of $143.19. The company has a debt-to-equity ratio of 0.43, a current ratio of 2.44 and a quick ratio of 1.58. The firm has a market cap of $9.00 billion, a P/E ratio of -4.57, a P/E/G ratio of 3.43 and a beta of 1.59. The stock’s 50-day moving average is $90.00 and its 200-day moving average is $92.48.

Albemarle (NYSE:ALB) last announced its earnings results on Wednesday, February 12th. The specialty chemicals company reported ($1.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.49). Albemarle had a positive return on equity of 1.67% and a negative net margin of 28.80%. Sell-side analysts anticipate that Albemarle Co. will post -1.55 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO J Kent Masters sold 2,525 shares of the firm’s stock in a transaction dated Thursday, December 5th. The shares were sold at an average price of $101.12, for a total value of $255,328.00. Following the completion of the sale, the chief executive officer now directly owns 73,747 shares in the company, valued at approximately $7,457,296.64. This trade represents a 3.31 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. 0.38% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Albemarle

A number of institutional investors have recently bought and sold shares of ALB. Quarry LP lifted its stake in shares of Albemarle by 1,400.0% during the 3rd quarter. Quarry LP now owns 270 shares of the specialty chemicals company’s stock worth $26,000 after buying an additional 252 shares during the last quarter. Assetmark Inc. lifted its position in Albemarle by 340.6% during the fourth quarter. Assetmark Inc. now owns 304 shares of the specialty chemicals company’s stock worth $26,000 after acquiring an additional 235 shares during the last quarter. Trust Co. of Vermont boosted its holdings in shares of Albemarle by 606.5% during the fourth quarter. Trust Co. of Vermont now owns 325 shares of the specialty chemicals company’s stock worth $28,000 after acquiring an additional 279 shares during the period. Eastern Bank acquired a new position in shares of Albemarle in the third quarter valued at approximately $31,000. Finally, Cromwell Holdings LLC increased its stake in shares of Albemarle by 61.9% during the third quarter. Cromwell Holdings LLC now owns 387 shares of the specialty chemicals company’s stock worth $37,000 after purchasing an additional 148 shares during the period. Institutional investors and hedge funds own 92.87% of the company’s stock.

Albemarle Corporation develops, manufactures, and markets engineered specialty chemicals worldwide. It operates through three segments: Energy Storage, Specialties and Ketjen. The Energy Storage segment offers lithium compounds, including lithium carbonate, lithium hydroxide, and lithium chloride; technical services for the handling and use of reactive lithium products; and lithium-containing by-products recycling services.